⚠️
Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Elevated cost per beneficiary
Risk indicators are statistical patterns, not allegations. Learn more
11,773
Total Claims
$4.3M
Drug Cost
896
Beneficiaries
$4,790
Cost/Patient
Risk Score Breakdown 3/100
Low (0)Moderate (15)Elevated (30)High (50+)
Cost per patient outlier+3
Score components are additive. Read full methodology
Peer Comparison vs. 6,382 Endocrinology providers
+22%
Cost per patient vs peers
$4,790 vs $3,933 avg
+7%
Brand preference vs peers
54.7% vs 51.2% avg
Brand vs Generic
45% generic
Brand: 5,868 claims · $4.0M
Generic: 4,850 claims · $211K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Semaglutide | 464 | $516K |
| Empagliflozin | 542 | $507K |
| Insulin Lispro | 555 | $353K |
| Insulin Aspart | 419 | $317K |
| Linagliptin | 222 | $182K |
| Dulaglutide | 124 | $179K |
| Sitagliptin Phosphate | 188 | $178K |
| Insulin Glargine,hum.Rec.Anlog | 359 | $169K |
| Sitagliptin Phos/Metformin Hcl | 211 | $167K |
| Sitagliptin Phos/Metformin Hcl | 209 | $123K |
| Dapagliflozin Propanediol | 153 | $113K |
| Cinacalcet Hcl | 152 | $89K |
| Insulin Glargine,hum.Rec.Anlog | 205 | $84K |
| Insulin Degludec | 114 | $83K |
| Insulin Glargine/Lixisenatide | 82 | $69K |
Prescribing Profile
Patient Profile
74
Avg Age
65%
Female
1.59
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About